Skip to main content
OpenTrials
Completed

NCT Number: NCT01516177

Associating Renal Transplantation With the ITN Signature of Tolerance

This is an observational study for people who have received a kidney transplant within the past 1 to 5 years. Researchers in this study are looking for a certain pattern of genes and cells in the blood that has been found in a group of rare transplant patients who do not need immunosuppression. The study goal is to find out how common this pattern is in transplant patients, as a first step in determining if it can be used to personalize anti-rejection drug regimens better.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alabama Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

Following surgery, kidney transplant patients must take medications in order to prevent rejection of their transplanted organ. These medications can be very effective. Called immunosuppressive drugs, they work by reducing the activity of the immune system. Because of this, however, they can also have serious side effects, including increased risks of serious infections and certain types of cancer.

The ITN Registry of Tolerant Kidney Transplant Recipients recently identified a rare group of people whose immune system has accepted their transplant without continued use of immunosuppressive drugs. Researchers have found that these patients have a unique pattern of cells and genes expressed in their blood compared to other transplant patients.

The ARTIST study will ask the questions "Are there other transplant patients who show this pattern?" and "If so, how often?"

The goal is to find out if there are other transplant patients who are taking immunosuppression who also show this pattern of genes. If there are others, then this pattern may one day be useful in identifying transplant patients who could reduce the dose of immunosuppression they need without fear of rejection.

Researchers are seeking adults who have received a kidney transplant within the past 1 to 5 years. Participants will be asked to attend 3 short appointments with study doctors over a period of 2 years. At these visits, doctors will request demographic and clinical information, relevant medical histories and blood and urine samples. Participants will be compensated for their time.

It is important to note that this is an observational study only. Other than receiving consultations and advice from the transplant team, there is no direct medical benefit to participating. However, by participating, patients may play an active part in helping doctors learn to control kidney transplant rejection more effectively, with fewer drugs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Received first kidney transplant from a living or deceased donor.
  • Kidney transplanted between 1 and 5 years ago.
  • Calculated GFR of greater than or equal to 45 mL/min/1.73 m2 within last 6 months
  • Ability to understand and provide informed consent.

Exclusion criteria

  • History of steroid-resistant acute rejection
  • History of two or more episodes of acute rejection
  • Any acute rejection in the past year
  • Current malignancy
  • Transplant of another organ
  • AIDS according to the CDC definition of AIDS.

Treatment and study plan

Primary outcomes

  1. The presence of at least one time point of the previously identified renal transplant tolerance signature.

    Time frame: 2 years

Secondary outcomes

  1. Time course of potential changes in the previously identified renal transplant tolerance signature in individual participants.

    Time frame: 2 years

  2. Expression levels for a wide variety of genes measured by large-scale microarray or by PCR assessments

    Time frame: 2 years

  3. Flow-cytometric measurements of cell populations distinguished by cell-surface phenotype

    Time frame: 2 years

  4. Selected clinical events and laboratory parameters to assess hematologic and renal function

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Nih

Collaborators

  • Clinical Trials in Organ Transplantation
  • Immune Tolerance Network (ITN)

Registry information

Official study title

An Observational Study to Assess the Prevalence of a Tolerance Signature in Renal Transplant Recipients (ITN524ST/CTOT-12)

Acronym: ARTIST

Important dates

Study start
2010
Primary completion
2014
Study completion
2014
First posted
Jan 24, 2012
Registry last updated
Dec 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.